Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports ...
GlobalData on MSN2d
Rigel enrols first subject in Phase I sickle cell disease therapy trialRigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...
Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Rigel Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K.
Rigel Pharmaceuticals (RIGL) announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating ...
For investors seeking deeper insights, InvestingPro offers exclusive analysis and 14 additional ProTips for Rigel Pharmaceuticals. The platform's comprehensive Fair Value analysis suggests the ...
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel (RIGL – Research Report) and keeping the price target at ...
KFDA approves immune thrombocytopenia treatment Tavalisse from Rigel Pharmaceuticals KFDA greenlights Tavalisse, a ...
This article is based on a press release statement from Rigel Pharmaceuticals (NASDAQ:RIGL), Inc. The company maintains a healthy financial position with a current ratio of 1.96 and operates with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback